U.S. markets open in 4 hours 5 minutes
  • S&P Futures

    +23.50 (+0.61%)
  • Dow Futures

    +225.00 (+0.72%)
  • Nasdaq Futures

    +86.25 (+0.66%)
  • Russell 2000 Futures

    +27.30 (+1.22%)
  • Crude Oil

    +0.87 (+1.46%)
  • Gold

    -8.40 (-0.48%)
  • Silver

    -0.18 (-0.67%)

    +0.0013 (+0.11%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -0.53 (-2.27%)

    +0.0027 (+0.20%)

    +0.1990 (+0.19%)

    +2,366.28 (+4.82%)
  • CMC Crypto 200

    +39.35 (+3.98%)
  • FTSE 100

    +73.70 (+1.11%)
  • Nikkei 225

    +150.93 (+0.51%)

Did Business Growth Power ProPhase Labs's (NASDAQ:PRPH) Share Price Gain of 131%?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
  • Oops!
    Something went wrong.
    Please try again later.

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can make much more than 100% if the company does well. For example, the ProPhase Labs, Inc. (NASDAQ:PRPH) share price has soared 131% in the last three years. That sort of return is as solid as granite.

Check out our latest analysis for ProPhase Labs

ProPhase Labs isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

In the last 3 years ProPhase Labs saw its revenue grow at 83% per year. That's much better than most loss-making companies. Meanwhile, the share price performance has been pretty solid at 32% compound over three years. This suggests the market has recognized the progress the business has made, at least to a significant degree. That's not to say we think the share price is too high. In fact, it might be worth keeping an eye on this one.

You can see how revenue and earnings have changed over time in the image below, (click on the chart to see cashflow).

NasdaqCM:PRPH Income Statement, April 28th 2019
NasdaqCM:PRPH Income Statement, April 28th 2019

If you are thinking of buying or selling ProPhase Labs stock, you should check out this FREE detailed report on its balance sheet.

What about the Total Shareholder Return (TSR)?

We'd be remiss not to mention the difference between ProPhase Labs's total shareholder return (TSR) and its share price return. Arguably the TSR is a more complete return calculation because it accounts for the value of dividends (as if they were reinvested), along with the hypothetical value of any discounted capital that have been offered to shareholders. We note that ProPhase Labs's TSR, at 238% is higher than its share price return of 131%. When you consider it hasn't been paying a dividend, this data suggests shareholders have benefitted from a spin-off, or had the opportunity to acquire attractively priced shares in a discounted capital raising.

A Different Perspective

It's nice to see that ProPhase Labs shareholders have received a total shareholder return of 49% over the last year. That gain is better than the annual TSR over five years, which is 17%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. You might want to assess this data-rich visualization of its earnings, revenue and cash flow.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.